All In Biotech

Drug Trial Radar · NCT07813572

ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular

A Phase 3, Randomized, Open-Label, Active-Controlled, Multicenter Study of ZG005 in Combination With Bevacizumab Versus Sintilimab in Combination With Bevacizumab in the First-Line Treatment of Advanced Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Oct 20, 2026

Primary completion

Sep 2031

Study completion Sep 2032

Sponsor

Sponsor type
Industry
First posted
Sep 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy of ZG005 combined with bevacizumab compared with sintilimab combined with bevacizumab in the first-line treatment of participants with advanced HCC

Conditions

  • Hepatocellular Carcinoma

Interventions

  • ZG005 for InjectionDrug

    Participants receive ZG005 20 mg/kg IV, Q3W

  • Bevacizumab ( Avastin)Drug

    Participants receive Bevacizumab ( Avastin) 15 mg/kg IV, Q3W

  • SintilimabDrug

    Participants receive Sintilimab 200mg IV, Q3W

  • BevacizumabDrug

    Participants receive Bevacizumab 15 mg/kg IV, Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: up to 3 years
  2. Overall survival (OS)Time frame: up to 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanjing Tianyinshan Hospital

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.